t(8;16) AML developed subsequent to breast cancer therapy

Şahin, Feride İffet; Yılmaz, Zerrin; Karakuş, Sema; Boğa, Salih; Akçali, Z.; Demirhan, Beyhan

doi:10.1080/10245330600775030

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alkylating agent-associated AML is usually diagnosed 3 to 7 years after treatment of the etiology. Chromosome 5 and/or 7 abnormalities were more common in cytogenetic analysis of AML patients ( 15 ). In contrast, AML associated with topoisomerase II inhibitors has a short incubation period and is typically presented as a translocation abnormality of 11q23, 21q22, or other chromosomes ( 16 ).…”

Section: Discussionmentioning

confidence: 99%

Metachronous Multiple Primary Carcinoma With Acute Promyelocytic Leukemia: 2 Cases Report and Literature Review

Shen¹,

Zhang²,

Guo³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

The co-occurrence of multiple primary cancers with hematological malignancies is uncommon, and acute promyelocytic leukemia (APL) with MPC is even rarer, with only a few cases reported in the literature. Herein, we introduce the diagnosis and treatment of 2 cases of MPC complicated with APL in our hospital and review the relevant literature. Both patients were primary solid tumor patients and were treated with surgery and chemotherapy, and had stable disease (SD). However, more than 1 year after the primary tumor was diagnosed, clinical symptoms were found and APL was diagnosed. Both patients received standard remission-induction therapy, but unfortunately died in the short term due to hemorrhagic complications. In conclusion, treatment of hematological neoplasms, especially acute leukemia combined with multiple primary cancers, is challenging. The prognostic factors and survival analysis of MPC patients with combined APL still need further clinical research and analysis.

show abstract

Section: Discussionmentioning

confidence: 99%